1. Introduction {#s0005}
===============

Psychosis is a debilitating disorder characterised by hallucinations, delusions and thought disorder, that affects approximately 4 in 1000 individuals in the UK each year ([@bb0095]). It is a core feature of severe mental illnesses, such as schizophrenia and bipolar disorder, where treatment commonly involves the long-term use of anti-psychotic medication. However, the response to antipsychotics varies between patients, and is associated with the burden of significant side-effects. In order to find a tolerable treatment, it is often necessary for newly diagnosed patients to trial multiple antipsychotics. Developing a better understanding of psychosis subtypes could therefore benefit patients by identifying biomarkers that correlate with medication tolerance.

Schizophrenia and Bipolar disorder are both thought to be highly heritable, and recent genome wide association studies suggest that hundreds of common genetic variants contribute to disease risk ([@bb0150]). The most prominent results from schizophrenia genetic studies have been associations to the major histocompatibility complex (MHC) locus, which implicates the immune system. Transcriptomic studies in blood have also consistently identified disruptions in immune pathways both in schizophrenia ([@bb0055]) and in bipolar disorder ([@bb0080]). Recent meta analyses of transcriptome data have further strengthened these findings and found common and abnormal cytokine patterns in patients with chronic depression, bipolar disorder or schizophrenia ([@bb0065]).

While psychosis is obviously closely linked to the brain, expression changes, are not necessarily linked to brain tissue. Peripheral gene expression changes can plausibly be detected in blood, especially in the case of the immune system. In a meta-analysis of Schizophrenia transcriptomics ([@bb0075]) that pooled 18 previously published blood and brain-based studies the authors found significant overlap in dysregulated pathways between both tissues, including the upregulation of innate immune pathways. Blood based transcriptomic studies have the additional advantage of capturing complex gene environment interactions, at key points during disease progression. This includes first episode psychosis which is of special interest since patients will get treatment for the first time, following an acute episode of symptoms.

However, there are few studies that focus specifically on the transcriptome of first episode psychosis (FEP) patients, when they first encounter mental health services. One notable exception is a Singaporean study which identified a 400 gene signature to distinguish FEP patients and healthy controls ([@bb0105]), however this study was limited to 26 patients and did not distinguish between positive and negative symptom dimensions.

To investigate the potential relationship between psychosis specific gene expression changes, and diagnostic/symptom dimensions, we make use of the Genetics and Psychosis (GAP) study ([@bb0030]). GAP contains transcriptome data derived from the whole blood of healthy controls (HC), as well as FEP patients. While these patients did receive anti-psychotic medication where necessary, they were recruited within one week of admission to hospital, and exposure to medication was therefore limited compared to chronic psychosis sufferers\' who may have taken medication continuously for many years.

We report the results of a case-control differential gene expression (DGE) and pathways analysis using the GAP transcriptome data. This is followed by investigating the correlation between psychosis pathways and symptom dimensions. Finally, we compare how the disruption of pathways differs in FEP patients who qualify for a Schizophrenia diagnosis and those who do not.

2. Methods and materials {#s0010}
========================

2.1. Ethics {#s0015}
-----------

The Genetics and Psychotic Disorders (GAP) Study received ethical approval from the South London and Maudsley NHS Foundation Trust (SLaM), as well as from the Institute of Psychiatry, Psychology and Neuroscience Local Research Ethics Committee, IOPPN/SLaM research ethics approval number: 135/05. Informed written consent was obtained from all participants in the study by the GAP team.

2.2. Study design and participants {#s0020}
----------------------------------

As part of the GAP study ([@bb0030], [@bb0040]), Patients aged 18 to 65 years who presented with first-episode psychosis at the inpatient units of SLaM were approached for recruitment. Patients were invited to participate if they met the ICD-10 criteria for a diagnosis of non-affective (F20 to F29) or affective (F30 to F33) psychosis ([@bb0070]), validated by administration of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) ([@bb0005]), they were re-contacted after the start of treatment.

Between May 1, 2005, and May 31, 2011, 461 patients with first-episode psychosis were recruited. The cohort consisted of a diverse multi-ethnic population. Further patient information, blood samples and genetic ancestry were acquired as described previously ([@bb0035]). During the same period, a total of 389 control individuals were recruited. These individuals were aged 18--65 years and were similar to the local population regarding gender, ethnic origin, education, employment status and socio-economic status. Recruitment of controls was done using Internet and newspaper advertisements and by distributing leaflets at train stations, shops, and job centres. Volunteers were administered the Psychosis Screening Questionnaire ([@bb0015]) and were excluded if they met the criteria for a psychotic disorder or if they reported a previous diagnosis of psychotic illness.

The OPCRIT system ([@bb0155]) was used to assign ICD-10 and DSM-IV diagnostic categories in a systematic way. For subset analyses including diagnosis, patients who fit the diagnostic criteria for schizophrenia under either the ICD or DSM system were assigned to the schizophrenia (Scz) group, while all other patients were assigned to the other psychosis group (OP).

2.3. RNA processing and quality control {#s0025}
---------------------------------------

Whole blood samples were collected using PAXgene tubes for RNA, from a subset of GAP participants (227 cases and 168 controls) within the first two weeks of recruitment. Samples were run at the NIHR Maudsley Biomedical Research Centre for Mental Health (BRC-MH) microarray facility at the SGDP, Institute of Psychiatry, Psychology and Neuroscience, King\'s College London, UK. Microarrays where run in accordance with the manufacturer\'s protocol using Illumina HT-12 V4 bead-chips (Illumina, USA).

All analysis was performed using R version 3.1.2. Pre-processing of the data was performed using an in-house developed pipeline.

The pipeline takes raw gene expression data exported from Illumina\'s Genomestudio, performs background correction ([@bb0170]) using negative bead expression levels in order to correct for noise. Lumi (version 2.22.1 [@bb0050]) was used to log base 2 transform the data followed by robust spline normalization ([@bb0050]). Outlying samples were iteratively identified using fundamental network concepts and removed, following the methods described by [@bb0135].

In order to reduce the influence of batch effects we adjusted for technical categorical variables using multiple linear regression and ComBat ([@bb0115]). Other Continuous technical artefacts were accounted for by taking the first principal component across housekeeping and undetected probes and regressing this against technical variables. Four variables were significantly associated with PC1, these were as follows: "The date that Samples were thawed", "Concentration of initial RNA", "Concentration of labelled cRNA" and "Date of RNA purification". They were regressed against expression for each probe, and the mean adjusted residuals where taken forward for all further analysis. The RNA integrity number (RIN) was include in the list of variables but was not significantly correlated with the first principle component. We did not use a RIN cut-off, to preserve sample size, as a result 24 samples had a RIN between 8 and 5.

The expression data was further tested for hidden covariates using surrogate variable analysis ([@bb0110]). FEP and Control status was included in the model to preserve the biological signal between groups. Following this we compared recorded gender with gender determined by XIST and PRKY probes and excluded samples that showed a mismatch. Finally, we excluded all probes that could not be reliably detected in 80% of the samples in at least one diagnostic group. We used the R package CellMix version 1.6 ([@bb0060]), to test for potential significant differences in whole blood cell populations between cases and controls and these were included in limma models.

2.4. Differential expression analysis {#s0030}
-------------------------------------

Standard Differential expression analysis was performed using the R package LIMMA ([@bb0160]) (version 3.26.8). Prior to analysis we accounted for potential covariates by performing multiple linear regression on all probes with CellMix proportions, age, sex and ethnicity as independent variables. Mean adjusted residuals were used in all subsequent analysis. Probes were declared significantly differentially expressed if the FDR adjusted q-value was \<0.05 and the absolute log fold change was above 0.1. Differential expression was firstly tested in first episode psychosis (FEP) group vs healthy controls followed by a subgroup analysis comparing the Schizophrenia (Scz) and Other Psychosis (OP) groups with healthy controls.

2.5. Symptom severity {#s0035}
---------------------

Illness severity was assessed by using the Positive and Negative Syndrome Scale (PANSS) ([@bb0090]), which consists of 30 questions, each ranging from 1 (not present) to 7 (extreme). The PANSS is subdivided into 3 subscales with the positive and negative subscales containing 7 questions each and the general psychopathology subscale containing 16 questions.

Correlation between patient PANSS scores and differentially expressed probes was calculated using Pearson\'s r, implemented by the rcorr function in the Hmisc r package. Probe correlations with a p-value below 0.05 were filtered out. Remaining probes were used in gene enrichment analysis.

2.6. Gene enrichment analysis {#s0040}
-----------------------------

All enrichment analysis was performed using the UserListEnrichment function of the WGCNA package ([@bb0100]). Enrichment analysis, for the results of the LIMMA analysis, was performed by testing differentially expressed probes (q-value≤0.05 and logFC \>0.1). All probes that did not pass the q-value threshold were included as background.

In all cases KEGG ([@bb0085]) and GO ([@bb0010]) databases taken from the Enrichr website were used (<http://amp.pharm.mssm.edu/Enrichr/st> accessed 05. July.2016). The databases used were KEGG 2016, GO Molecular Function 2015, GO Cellular Component and GO Biological Process 2015. Additionally, internal lists from the UserListEnrichment function in WGCNA were used. These were Brain Modules (useBrainLists), Brain Region Markers (useBrainRegionMarkers) and Blood Atlases (useBloodAtlases). Gene lists specifically compiled for Psychosis were included from publications by [@bb0145] and [@bb0140]. Result categories that contained \<20 overlapping probes were filtered out.

2.7. Anti-psychotic medication {#s0045}
------------------------------

Psychosis patients were received standard care (including anti-psychotics where necessary) until they were stabilised, and blood samples were then obtained within the first two weeks of recruitment. To assess the effect of medication on gene expression, we first identified the antipsychotics medication that patients were taking at the time of blood collection. We grouped FEP samples based on the three most common antipsychotic categories which were as follows: Olanzapine (N = 46), Risperidone (N = 27) and antipsychotic free (N = 18). We performed differential expression analysis between the three medication groups and controls.

3. Results {#s0050}
==========

3.1. Sample characteristics {#s0055}
---------------------------

Demographics data is shown in [Table 1](#t0005){ref-type="table"}. Transcriptomic data was available for 280 samples, 149 of these corresponded to healthy controls (HC), and 131 to first episode psychosis (FEP) patients. The FEP group further consisted of 68 patients with a Schizophrenia diagnosis and 63 patients with other psychoses, according to the OPCRIT system ([@bb0155]). The other psychosis group primarily fit the DSM-IV categories of mania (n = 16), schizo-affective disorder (n = 15), depression with psychosis (n = 12) and psychosis NOS (n = 10) (see [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). FEP with a diagnosis of Schizophrenia was on average younger than other FEP patients and controls. FEP patients had similar exposures to antipsychotic medication, independently from diagnosis, with Olanzapine and Risperidone being the most common. FEP on average had mild to moderate symptoms according to PANSS assessment ([@bb0120]), with those with a diagnosis of schizophrenia presenting with slightly higher scores for positive and negative symptoms subscales than FEP with other psychoses (see [Table 1](#t0005){ref-type="table"}).

3.2. Differential expression analysis {#s0060}
-------------------------------------

We identified 978 differentially expressed genes between FEP and HC, 509 of these were upregulated and 469 were downregulated in FEP. The most significantly upregulated genes were SUMO3, CAMP, DEFA1B, DEFA1 and DEFA3. The most significantly downregulated genes were HNRNPUL2, RBM14, TMEN69, SCAP and FAM110A (see [Table 2](#t0010){ref-type="table"}, and [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}).

Gene Enrichment analysis identified 116 significant pathways. They overlapped substantially, and fundamentally corresponded to just a handful of distinct gene lists and pathways, including ribosomal function/transcription regulation, immune signalling, and energy metabolism (see [Table 3](#t0015){ref-type="table"}, [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}).

All 978 differentially expressed probes were correlated with the PANSS subscales. For the positive and negative subscales, we identified 120 and 37 significantly correlated probes respectively ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}). Gene enrichment analysis of probes found positive symptoms were correlated with immune pathways (NF-κB, Ras and cytokine signalling), while negative symptoms were correlated to ribosomal pathways (see [Table 4](#t0020){ref-type="table"} and [Supplementary Table 4](#ec0020){ref-type="supplementary-material"}).

3.3. Differences between schizophrenia and other psychosis {#s0065}
----------------------------------------------------------

In order to explore differences in FEP subgroups we replicated analyses by independently comparing the Schizophrenia (Scz) and Other Psychosis (OP) groups with healthy controls (HC). Analysis using a Scz vs OP design was also performed, but no significantly differentially expressed genes were identified (results not shown).Table 1Demographics.Table 1Healthy control (n = 149)First Episode Psychosis (n = 131)Schizophrenia (n = 68)Other psychosis (n = 63)p-valueSex = MALE (%)86 (57.7)45 (66.2)31 (49.2)0.145Age (mean (sd))29.87 (10.53)26.59 (7.67)30.03 (9.22)0.047Ethnicity (%)0.102 Asian10 (6.7)6 (8.8)6 (9.5) Black43 (28.9)33 (48.5)22 (34.9) Other10 (6.7)5 (7.4)5 (7.9) White86 (57.7)24 (35.3)30 (47.6)PANSS scores (mean (sd)) Positive scale16.70 (6.88)15.49 (6.00)0.344 Negative scale17.20 (6.90)14.76 (6.08)0.065Anti-psychotic type (%)0.6 Antipsychotic free9 (13.2)9 (14.3) Olanzapine22 (32.4)24 (38.1) Risperidone14 (20.6)13 (20.6) Amisulpride0 (0.0)1 (1.6) Aripiprazole9 (13.2)3 (4.8) Haloperidol2 (2.9)4 (6.3) Quetiapine4 (5.9)2 (3.2) Sulpiride1 (1.5)0 (0.0) Trifluoperazine1 (1.5)0 (0.0) Unknown6 (8.8)7 (11.1)[^1]Table 2Top differentially expressed probes.Table 2GeneFEP vs HCScz vs HCOP vs HCChrTop 50 Up-regulated - logFC (q-value)CAMP0.66 (\<0.001)0.94 (\<0.001)0.38 (0.058)3DEFA1B0.97 (\<0.001)1.25 (\<0.001)0.69 (0.042)8DEFA30.95 (\<0.001)1.24 (\<0.001)0.66 (0.046)8DEFA10.87 (\<0.001)1.1 (\<0.001)0.64 (0.041)8C9ORF720.24 (\<0.001)0.3 (\<0.001)0.19 (0.041)9CLNS1A0.18 (\<0.001)0.23 (\<0.001)0.13 (0.049)11SUMO30.11 (\<0.001)0.12 (\<0.001)0.1 (0.022)21TMEM170B0.3 (\<0.001)0.36 (\<0.001)0.25 (0.037)6PSMC20.14 (\<0.001)0.18 (\<0.001)0.1 (0.050)7HBXIP0.1 (\<0.001)0.13 (\<0.001)0.07 (0.053)1PARL0.1 (\<0.001)0.12 (\<0.001)0.07 (0.048)3IFNGR10.16 (\<0.001)0.19 (\<0.001)0.12 (0.050)6GLRX0.24 (\<0.001)0.29 (\<0.001)0.19 (0.042)5IDH10.14 (\<0.001)0.16 (\<0.001)0.12 (0.036)2TCEB10.14 (\<0.001)0.16 (\<0.001)0.11 (0.041)8CCPG10.17 (\<0.001)0.21 (\<0.001)0.13 (0.046)15LYPLAL10.18 (\<0.001)0.2 (\<0.001)0.16 (0.037)1SLC30A90.18 (\<0.001)0.2 (\<0.001)0.15 (0.037)4TMBIM40.08 (\<0.001)0.1 (\<0.001)0.07 (0.044)12FAM96A0.25 (\<0.001)0.29 (\<0.001)0.2 (0.040)15FAM45A0.13 (\<0.001)0.16 (\<0.001)0.1 (0.048)10GNG100.31 (\<0.001)0.39 (\<0.001)0.24 (0.053)9C14ORF1000.15 (\<0.001)0.17 (\<0.001)0.12 (0.040)14COX7A20.22 (\<0.001)0.27 (\<0.001)0.18 (0.046)6TAF70.2 (\<0.001)0.24 (\<0.001)0.17 (0.040)5MAP2K1IP10.21 (\<0.001)0.25 (\<0.001)0.17 (0.046)4CRLS10.21 (\<0.001)0.24 (\<0.001)0.17 (0.041)20COX7A2L0.19 (\<0.001)0.21 (\<0.001)0.16 (0.037)2ATP5C10.24 (\<0.001)0.29 (\<0.001)0.2 (0.045)10FBXL50.13 (\<0.001)0.15 (\<0.001)0.1 (0.049)4UQCRQ0.28 (\<0.001)0.33 (\<0.001)0.23 (0.046)5BNIP20.18 (\<0.001)0.19 (\<0.001)0.16 (0.037)15SLC35A10.19 (\<0.001)0.23 (\<0.001)0.15 (0.059)6RPSA0.16 (\<0.001)0.2 (\<0.001)0.12 (0.061)3LYST0.14 (\<0.001)0.16 (\<0.001)0.12 (0.046)1WDR610.13 (\<0.001)0.16 (\<0.001)0.11 (0.044)15SRP90.2 (\<0.001)0.22 (\<0.001)0.18 (0.038)1VBP10.22 (\<0.001)0.25 (\<0.001)0.19 (0.041)XPCMT10.14 (\<0.001)0.14 (\<0.001)0.13 (0.036)6TMX10.25 (\<0.001)0.29 (\<0.001)0.2 (0.048)14SLC44A10.18 (\<0.001)0.19 (\<0.001)0.16 (0.036)9PRDX30.13 (\<0.001)0.14 (\<0.001)0.12 (0.037)10COX170.13 (\<0.001)0.15 (\<0.001)0.11 (0.042)3KIAA16000.19 (\<0.001)0.22 (\<0.001)0.15 (0.050)10PIGY0.17 (\<0.001)0.2 (\<0.001)0.15 (0.044)4COMMD30.17 (\<0.001)0.21 (\<0.001)0.14 (0.049)10KBTBD110.16 (\<0.001)0.19 (\<0.001)0.13 (0.050)8TMEM14B0.16 (\<0.001)0.19 (\<0.001)0.13 (0.055)6VAMP70.15 (\<0.001)0.16 (\<0.001)0.14 (0.036)XYLDHA0.11 (\<0.001)0.11 (\<0.001)0.11 (0.036)11  Top 50 Down-regulated - logFC (q-value)RBM14−0.13 (\<0.001)−0.17 (\<0.001)−0.09 (0.046)11HNRNPUL2−0.19 (\<0.001)−0.23 (\<0.001)−0.14 (0.040)11GABPB2−0.09 (\<0.001)−0.11 (\<0.001)−0.06 (0.053)1FAM110A−0.16 (\<0.001)−0.19 (\<0.001)−0.12 (0.046)20SCAP−0.14 (\<0.001)−0.17 (\<0.001)−0.11 (0.046)3PNPT1−0.11 (\<0.001)−0.14 (\<0.001)−0.08 (0.050)2RASGRP2−0.12 (\<0.001)−0.15 (\<0.001)−0.09 (0.050)11ZC3H5−0.11 (\<0.001)−0.13 (\<0.001)−0.08 (0.057)TMEM69−0.11 (\<0.001)−0.13 (\<0.001)−0.1 (0.037)1CLSTN1−0.16 (\<0.001)−0.2 (\<0.001)−0.12 (0.058)1GANAB−0.12 (\<0.001)−0.15 (\<0.001)−0.09 (0.054)11DENND4B−0.12 (\<0.001)−0.14 (\<0.001)−0.09 (0.046)1ZNF296−0.16 (\<0.001)−0.19 (\<0.001)−0.13 (0.042)19KIAA1267−0.1 (\<0.001)−0.13 (\<0.001)−0.08 (0.051)17CXXC1−0.12 (\<0.001)−0.14 (\<0.001)−0.1 (0.046)18POM121C−0.13 (\<0.001)−0.16 (\<0.001)−0.1 (0.049)7RANGAP1−0.12 (\<0.001)−0.15 (\<0.001)−0.1 (0.050)22STIP1−0.14 (\<0.001)−0.17 (\<0.001)−0.1 (0.060)11ITPKB−0.13 (\<0.001)−0.16 (\<0.001)−0.1 (0.055)1CD97−0.16 (\<0.001)−0.2 (\<0.001)−0.13 (0.053)19HGS−0.1 (\<0.001)−0.13 (\<0.001)−0.08 (0.060)17SUPT5H−0.14 (\<0.001)−0.16 (\<0.001)−0.11 (0.042)19UBQLN4−0.12 (\<0.001)−0.14 (\<0.001)−0.1 (0.044)1SPG7−0.11 (\<0.001)−0.13 (\<0.001)−0.08 (0.058)16RAB11FIP1−0.14 (\<0.001)−0.16 (\<0.001)−0.12 (0.046)8TRIM28−0.14 (\<0.001)−0.16 (\<0.001)−0.11 (0.053)19WDR23−0.12 (\<0.001)−0.13 (\<0.001)−0.1 (0.041)14GPS1−0.09 (\<0.001)−0.1 (\<0.001)−0.08 (0.046)17FBXO46−0.16 (\<0.001)−0.18 (\<0.001)−0.15 (0.041)19TLN1−0.21 (\<0.001)−0.24 (\<0.001)−0.18 (0.044)9ABCF1−0.11 (\<0.001)−0.13 (0.001)−0.09 (0.060)6ORC6L−0.1 (\<0.001)−0.11 (0.001)−0.08 (0.046)16UBA1−0.17 (\<0.001)−0.2 (0.001)−0.13 (0.061)XSRRM2−0.11 (\<0.001)−0.14 (0.001)−0.09 (0.057)16PDPR−0.21 (\<0.001)−0.24 (0.001)−0.18 (0.047)XRCC6−0.13 (\<0.001)−0.14 (0.001)−0.11 (0.046)22LBA1−0.18 (\<0.001)−0.21 (0.001)−0.16 (0.048)3GCN1L1−0.12 (\<0.001)−0.14 (0.001)−0.1 (0.052)12C21ORF58−0.12 (\<0.001)−0.14 (0.002)−0.1 (0.061)21EMD−0.09 (\<0.001)−0.1 (0.002)−0.07 (0.059)XST3GAL1−0.14 (\<0.001)−0.15 (0.002)−0.13 (0.037)8TSSC4−0.11 (\<0.001)−0.11 (0.002)−0.1 (0.037)11EDC4−0.1 (\<0.001)−0.11 (0.002)−0.1 (0.037)16CORO7−0.12 (\<0.001)−0.14 (0.002)−0.11 (0.048)16WASF2−0.18 (\<0.001)−0.2 (0.002)−0.17 (0.040)1UBA52−0.11 (\<0.001)−0.12 (0.002)−0.1 (0.044)19NRGN−0.3 (\<0.001)−0.33 (0.002)−0.26 (0.048)11AP1G2−0.11 (\<0.001)−0.11 (0.002)−0.1 (0.041)14KPNA6−0.12 (0.001)−0.14 (0.002)−0.1 (0.057)1PBX2−0.12 (\<0.001)−0.13 (0.002)−0.11 (0.041)6[^2][^3]Table 3Enriched Gene Sets: FEP vs HC.Table 3Gene setLibraryP-value\#Genes *Kyoto Encyclopedia of Genes and Genomes*RibosomeKEGG\<0.00146FAU, MRPL11, MRPL3, RPL17, RPL21, UBA52Oxidative phosphorylationKEGG\<0.00128ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRHParkinson\'s diseaseKEGG\<0.00127ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRHAlzheimer\'s diseaseKEGG\<0.00126ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRHHuntington\'s diseaseKEGG0.00126ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRH *Gene Ontology: Biological Process*Cytokine productionGOBP0.00714CASP1, CD46, G6PD, IL1B, PIK3CD, TBK1, TNFAIP8T cell receptorGOBP0.00916CARD11, CD3D, FYN, LAT, NCK1, RBCK1, UBE2NLeukocyte activationGOBP0.0237AIF1, ANXA1, CD3E, CD48, CD7, CD79A, CD93, CXCR4, FYN, FZD7, GAPT, ITGAL, LAT, LYL1, SP3, VAMP7Regulation of NF-kBGOBP0.04125BIRC2, CARD11, CASP1, CD36, CXXC5, FYN, HSPB1, IL1B, IRF3, RBCK1, UBE2NDefense response to BacteriaGOBP0.04311CAMP, CD36, DEFA1, FAU, HIST2H2BE, MYO1F, PGLYRP1, RPL39, TBK1, TNFAIP8   *Gene Ontology: Cellular Component*CytosolGOCC\<0.001238ATG3, BCR, DCP2, FYN, GMIP, GNAS, IL1B, IRF3, LYST, NDE1, NME1, PARK7, TBK1, UBA1, USP7Ribosomal subunitGOCC\<0.00145FAU, FXR2, MRPL3, RPL11, RPS15A, RPS3, RPS9NucleolusGOCC\<0.001127AATF, CD79B, HIF1A, ILF3, IP6K1, JUND, NIN, PCNA, PTEN, RNF7, RPL11, STAT3, ZFRMitochondrionGOCC0.00290ATP5L, COQ5, COX7C, CYBB, ILF3, NME1, NUBPL, OAS2, PARK7, REXO2, TPP1, UCP2LysosomeGOCC0.0129CTNS, CTSA, CTSB, CTSZ, CXCR4, FUCA1, GALC, HEXB, LAT, SRGN, TPP1, USP4   *Gene Ontology: Biological Process*RibosomeGOMF\<0.00145FAU, MRPL11, RPL27, RPS3, RPS3A, RPSAIon transportGOMF\<0.00118ATP5C1, ATP5E, COX6A1, NDUFA4, SLC9A1, UQCRH  *Blood Module Library (WGCNA)*Red Blood CellBlood\<0.001170ADD3, BAT3, CD48, IL8RB, JUND, LAMP2, LDHA, LYST, MED1, PARK7, STAT3, TBK1, UBN1Blood PlateletsBlood\<0.00139ACTN1, ANXA1, BCR, GNAS, GP9, JUND, LCN2, NRGN, TAGLN2, VCL   *Brain Module Library (WGCNA)*Post Synaptic Density ProteinsBrain\<0.001133AGL, BAT3, BCR, FASN, FYN, G6PD, HGS, MSN, MTDH, MYH9, NME1, SEPT5, SND1, TAGLN2, TBK1, TLN1, TUBB2C, UBA1, VAMP2Pyramidal Neurons (Amygdala)Brain\<0.00137ACSL4, CRBN, DDR1, ENY2, GMFB, HDAC2, MATR3, NME1, PCNA, TBK1, UBE3ADown in Alzheimer\'sBrain\<0.00180ACP1, ATP5O, ELMO1, GLO1, GMFB, GNAS, HEXB, ICA1, NME1, PARK7, STX7, TAF7, UBL3Glutamatergic synapseBrain\<0.00149ARF3, ATG3, BAT3, CABIN1, CENTB2, CPD, CTSD, DEK, GCA, GPR137, HGS, NRGN, PRNP, RARA, SPOCK2, SPTAN1, SRP9, TBCA, TIA1, UBE1, VAMP2CD40 stimulated Microglial cellsBrain\<0.00158ACP1, BCR, CARM1, DDR1, FYN, ILF3, IRF3, NME1, SLC9A1, TRIM28, UBE2L3, VAMP2[^4][^5]Table 4Gene sets correlated with symptom severity.Table 4Gene setLibraryP-value\#Genes *PANSS Positive symptom correlated pathways*MeaslesKEGG0.00348CD3E, CD46, FYN, IFNGR1, IL1B, IL2RB, IRF3, TBK1Cytokine productionGOBP0.0096CASP1, CD46, EOMES, IL1B, PTGS2, TBK1Regulation of NF-kB signallingGOBP0.01688CASP1, CXXC5, FYN, IL1B, IRF3, PELI1, PTGS2, TBK1Red Blood CellBlood0.019918BAZ2B, CD46, CKLF, COX7A2, DYNLT1, GALC, GNG10, IFNGR1, LYST, PELI1, PTGS2, RAB5A, RNF13, SHOC2, SRGN, TBK1, TNFAIP6, TXNRas signallingKEGG0.02199CSF1R, GNG10, LAT, RAB5A, RASAL3, RASGRP2, SHOC2, TBK1, ZAP70CytosolGOCC0.03531ALDOC, CAPZA2, CASP1, DPYD, FASN, FYN, IDH1, IL1B, IRF3, ITPKB, LYST, MATK, OSBPL7, PDE7A, PELI1, PTEN, RAP2C, TBK1, TXN, UBE2E1, USP7   *PANSS Negative symptom correlated pathways*Viral transcriptionGOBP\<0.0018RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6Cytosolic partGOCC\<0.0019AHR, RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6RibosomeGOMF\<0.0018RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6RibosomeKEGG\<0.0018RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6MitochondriaBrain0.00716COX6C, NDUFS5, PPA2, RPL11, RPL4, RPL5[^6][^7]Fig. 1Summary of Enrichment results for Schizophrenia and Other Psychosis.Venn diagram summarising and comparing Gene Set Enrichment results between Schizophrenia (Scz) and Other Psychoses (OP) groups. Differentially expressed genes from comparisons with healthy controls (HC) were used. A total of 8 gene set libraries with a combined 4479 categories were used. The Bonferroni corrected p-value cut-off for gene sets was 0.05. Pathways and functions associated with significant gene sets are highlighted in red (for pathways unique to a group) and green (for pathways present in both groups). The FEP vs HC comparison is not included since the results are a combination of the Scz and OP results.Fig. 1Fig. 2Gene Expression Change across Medication Groups.Heatmap comparing differential expression, between anti-psychotic medication groups and healthy controls. Anti-psychotic free (AF, N = 18), Olanzapine (Ola, N = 46) and Risperidone (Ris, N = 27) patients were compared to healthy controls (HC, N = 149). Results were subset to significant DE genes from the full FEP vs HC comparison, and fold change was plotted. The direction of gene expression tends to be preserved in the three comparisons.Fig. 2

Differential expression analysis of Scz vs HC identified 1276 differentially expressed genes, while the OP vs HC differential expression resulted in 284 significant genes (see [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}). Gene Enrichment identified 162 pathways in the Scz group, and 19 in the OP group, 15 of which were present in both groups. The 4 pathways unique to the OP group were related to NF-κB signalling, catabolic processes and transcriptional regulation of gene expression (see [Fig. 1](#f0005){ref-type="fig"}, [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}).

Differentially expressed genes were again correlated with PANSS subscales, and pathway analysis was performed. In the Scz group we identified 202 and 37 probes that were significantly correlated with positive and negative symptoms, respectively, while in the OP group we found 5 and 9 probes respectively ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}).

Pathway analysis of correlated probes was not performed for the OP group due to the low number of probes. For the Scz group, pathway analysis identified 11 pathways correlated with positive symptoms including immune pathways (lymphocyte/leukocyte activation, cytokine production), the cytosol, response to protein misfolding, exosome transport and four brain related pathways (neuronal cytoplasm, synaptome, glutamatergic synapse and post synaptic density). For negative symptoms the only pathway identified was related to RNA catabolism ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}).

3.4. Anti-psychotic medication {#s0070}
------------------------------

In the differential expression comparison between the three medication groups (Olanzapine, Risperidone, antipsychotic free \[AF\]) and controls, we identified no significant DE genes in the Risperidone - HC comparison, but did find 1132 and 338 DE genes in the Olanzapine - HC and AF - HC comparisons respectively (see [Supplementary Table 5](#ec0025){ref-type="supplementary-material"}). To visualise the effect of medication, we used the 978 significant DE genes from the full FEP -- HC comparison, and plotted the fold change for these genes in the three medication subsets (see [Fig. 2](#f0010){ref-type="fig"}), The direction (meaning up or down regulation) of differential expression compared to healthy controls was generally preserved across the three groups, but the magnitude (or fold change) of probes tended to be greater for the antipsychotic free group than for the olanzapine or risperidone groups, as can be seen in [Fig. 2](#f0010){ref-type="fig"}. In addition, no differentially expressed genes were found when comparing either of the antipsychotic groups with the antipsychotic free group.

4. Discussion {#s0075}
=============

4.1. First episode psychosis patients show deregulation in immune pathways {#s0080}
--------------------------------------------------------------------------

Our results suggest an immune deregulation component in psychosis patients, which is in line with expectations due to previous GAP studies ([@bb0125], [@bb0130]; [@bb0045]). Notably we find an upregulation of the antimicrobial α-defensins (DEFA1B, DEFA1 and DEFA3), which was independently reported for schizophrenia in a transcriptome study by [@bb0055]. Gene enrichment analysis revealed dysregulation in multiple pathways that are related to oxidative stress, NF-κB signalling and the Ribosome, which is consistent with the results by [@bb0075].

4.2. Patients meeting criteria for a diagnosis of schizophrenia have a more pronounced blood signature {#s0085}
------------------------------------------------------------------------------------------------------

We identified 1276 differentially expressed genes in the Scz vs HC comparison. This number was higher than what was found in similar gene expression studies of chronic schizophrenia ([@bb0055]), and may be explained by blood samples, in this study, being taken soon after patients were admitted to hospital, since the samples used in this study are first episode. As such the reported gene expression signature may more closely reflect the expression changes during acute psychosis, rather than during remission, and they might be less confounded by the effects of long-term antipsychotic treatment.

Comparing the result from Scz and OP analyses, we find more than fourfold as many differentially expressed genes, and pathways in the Schizophrenia group, probably reflecting the higher homogeneity. Interestingly 215 of the 284 dysregulated genes in the OP group, were also found in the Schizophrenia group. Furthermore, the direction of change was the same in both groups, although the log fold change in expression was lower for OP (see [Table 2](#t0010){ref-type="table"}). This suggests some common psychosis gene expression signature across diagnostic categories.

Interestingly 12 of the 19 significant pathways in the OP group are from brain specific pathway libraries, and all 12 were also identified in the Scz group ([Fig. 1](#f0005){ref-type="fig"}, [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}). A recent study pooling 18 schizophrenia transcriptome cohorts found that 50% of blood enriched pathways were also enriched in brain tissue ([@bb0075]). While we do not suggest that these results accurately reflect gene expression patterns in the brains of patients, it is interesting to note that the overlapping brain pathways include Alzheimer\'s Disease, the Amygdala and Microglial markers. This might be consistent with a neuro-inflammatory model of psychosis.

4.3. Positive symptom severity is correlated with immune function {#s0090}
-----------------------------------------------------------------

Interestingly, we found that positive symptom severity was correlated with immune pathways, both in the full FEP cohort, and in the Scz subset. One explanation for these results is that psychosocial and environmental stressors, trigger innate immune pathways, for example via the Hypothalamic pituitary adrenal (HPA) axis. This has been reported in previous FEP studies ([@bb0045]; [@bb0125]) and our results for positive symptoms are consistent with an upregulation in NF-κB signalling, which can be modulated by the above-mentioned stressors.

For the Scz subset we also found a correlation with multiple brain expressed categories, including glutamatergic synapses. Interestingly the glutamatergic signal was in part due to Neurogranin (NRGN), which was found to be downregulated in all groups, and this downregulation was significantly correlated with positive symptom severity in the Scz subset. NRGN was one of the first GWAS schizophrenia hits ([@bb0165]), and has been shown to be downregulated in brain tissue of schizophrenics ([@bb0020]).

In contrast pathways correlated with Negative symptom severity were less interpretable. This was partially because we only identified 38 probes that were significantly correlated to negative symptoms, while we identified 203 for positive symptoms (see [Supplementary Table 4](#ec0020){ref-type="supplementary-material"}). As a result, pathways for negative symptoms were almost exclusively driven by 8 ribosomal genes (RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6) (see [Table 4](#t0020){ref-type="table"}). As such our results in the most general terms suggest that negative symptom severity is correlated with changes in translation.

4.4. Anti-psychotic medication reduces magnitude of psychosis blood signature {#s0095}
-----------------------------------------------------------------------------

Our results suggest that the effect of antipsychotics reduces the detectable blood signature associated with psychosis, without introducing an overwhelmingly confounding gene expression signature specific to anti-psychotics. This is consistent with previous findings by [@bb0025], where antipsychotics appeared to shift expression levels towards what is seen in HC. This reduces the magnitude of a medication-naive psychosis blood signature and introduces a confounding in the overall signature by introducing medication specific changes. It should be noted that 8 antipsychotic medications were used to stabilise patients in this study, and these are likely to have different non-specific effects on gene expression. This is expected to reduce the confounding effect specific to a single drug in the overall FEP - HC results. Moreover, FEP were recruited shortly after their first contact with Mental Health services and therefore were on average within the first two weeks of pharmacological treatment.

4.5. Limitation {#s0100}
---------------

A major limitation of this study is that we were unable to control for several important confounders such as BMI, smoking, drugs and medications other than antipsychotics. It is possible that these factors could have a significant impact on cell composition and gene expression in whole blood. While we did use methods such as surrogate variable analysis to detect potential major unknown confounders, and CellMix to estimate variations in cell composition, it is ultimately not possible to adjust for all possible sources of variation.

4.6. Conclusion {#s0105}
---------------

Overall, we found evidence for multiple disrupted pathways in the blood of first episode psychosis patients, specifically in immune signalling and transcription/translation. In addition, we found that positive symptom severity correlated with genes involved in immune signalling while negative symptom severity correlated with changes in transcription. These signatures were more pronounced in individuals meeting the criteria for a diagnosis of schizophrenia, but they were detectable to some extent in other types of psychosis. These effects could not be attributed to anti-psychotic medication administered to stabilise patients, since anti-psychotic free patients showed higher magnitude changes in gene expression.
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[^1]: Table of Demographics for healthy control (HC) and first episode psychosis (FEP) groups. FEP patients are separated by diagnosis into Schizophrenia and Other Psychosis. The study included 280 individuals. Schizophrenia patients were found to be slightly younger than controls and other patients. No significant difference was found for Gender, Ethnicity, PANSS scores or Anti-psychotic type. Pvalues were calculated using the chi-square test for categorical variables, and t-test for continues variables.

[^2]: Table of logFC and q-value of top up and down regulated probes for 3 comparisons (FEP vs HC, SCZ vs HC and OP vs HC) following differential expression analysis. Each comparison contains the logFC value followed by the q-value in brackets. Genes were included if the FDR adjusted q-value was less than 0.05 and the absolute log fold change was above 0.1 in all 3 comparisons. For a complete list of probes see [supplementary table 2](#ec0010){ref-type="supplementary-material"}.

[^3]: Table of logFC and q-value of top up and down regulated probes for 3 comparisons (FEP vs HC, SCZ vs HC and OP vs HC) following differential expression analysis. Each comparison contains the logFC value followed by the q-value in brackets. Genes were included if the FDR adjusted q-value was less than 0.05 and the absolute log fold change was above 0.1 in all 3 comparisons. For a complete list of probes see supplementary table 2.

[^4]: Table of select gene sets enriched with differentially expressed (n = 978) genes between FEP and HC. P-values are Bonferroni corrected. Total number of DE genes present in each gene set are indicated in the \# column. List of gene sets and gene symbols is not exhaustive, for complete results see [supplementary table 2](#ec0010){ref-type="supplementary-material"}.

[^5]: Table of select gene sets enriched with differentially expressed (n = 978) genes between FEP and HC. P-values are Bonferroni corrected. Total number of DE genes present in each gene set are indicated in the \# column. List of gene sets and gene symbols is not exhaustive, for complete results see supplementary table 2.

[^6]: Table of gene sets enriched with DE genes significantly correlated to positive or negative symptoms in FEP. The 120 and 37 DE genes significantly correlated, respectively, with Positive and Negative symptoms were used for gene enrichment analysis. Significant pathways are shown separately for the two symptom dimensions. P-values are Bonferroni corrected. Total number of DE genes overlapping with gene sets are indicated in the \# column. For complete results, including genes correlated with symptom severity, see [supplementary table 4](#ec0020){ref-type="supplementary-material"}.

[^7]: Table of gene sets enriched with DE genes significantly correlated to positive or negative symptoms in FEP. The 120 and 37 DE genes significantly correlated, respectively, with Positive and Negative symptoms were used for gene enrichment analysis. Significant pathways are shown separately for the two symptom dimensions. P-values are Bonferroni corrected. Total number of DE genes overlapping with gene sets are indicated in the \# column. For complete results, including genes correlated with symptom severity, see supplementary table 4.
